Is NCT02974647 recruiting in East White Plains, NY?

Yes, NCT02974647 is currently recruiting participants at its East White Plains, NY location. This t cell lymphoma clinical trial is actively enrolling qualified participants.

How do I join the t cell lymphoma clinical trial in East White Plains?

To join this clinical trial in East White Plains, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this East White Plains clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

T Cell Lymphoma Clinical Trial in East White Plains, NY

About This T Cell Lymphoma Study in East White Plains

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Pathologically confirmed T or NK cell lymphoma at the enrolling institution. For CTCL, patients with stage IB disease or greater are eligible.

Relapse or refractory disease after at least 1 systemic therapy except for T-PLL, LGL, or T-cell Lymphoproliferative diseases with JAK2 fusion.

Untreated patients may be allowed after discussion with P.I.

Measurable disease defined by:

Lugano Classification for systemic lymphoma or

Atypical and or malignant lymphocytes quantifiable by flow cytometry or morphology in blood or bone marrow or

mSWAT \> 0 or Sezary count ≥ 1000 cells/μL for CTCL

Previous systemic anti-cancer therapy for T-cell lymphoma must have been discontinued at least 2 weeks prior to treatment.

Glucocorticoids aimed at controlling lymphoma-related symptoms are allowed as long as they are tapered down to 20mg or less by the time of ruxolitiib initiation

Topical steroids for CTCL are permitted

See section 6.2 Subject

Exclusion Criteria

for guideline regarding adjuvant and maintenance therapy for prior malignancy

Patients must meet the following lab criteria:

ANC ≥ 1.0/mm\^3 or ANC \>/= 0.5/mm\^3 (if patient has baseline neutropenia due to lymphoma), platelets ≥ 100 x 10\^9/L or ≥ 50 x 10\^9/L (if related to lymphoma), Hgb ≥ 8g/dL

Patients with LGL or T-PLL are not required to meet a minimum ANC or hemoglobin value for eligibility

Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or; ≤ 3 x ULN if documented hepatic involvement with lymphoma, or ≤ 5 x ULN if history of Gilbert's ; AST and ALT ≤ 3 x ULN; ≤ 5 x ULN if due to lymphoma involvement

Creatinine clearance ≥ 30 mL/min; creatinine clearance of 15-29 mL/min will be allowed as long as baseline platelets are ≥ 150 x 10\^9/L

For patients with positive hepatitis B core antibody or surface antigen, hepatitis B PCR must be negative and prophylaxis with entecavir or equivalent is required.

Patients with HIV are allowed provided that they are on anti-retroviral treatment with no active infections. Exclusion Criteria:

Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, uncontrolled diabetes, clinically significant pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

ECOG performance status \>2

Prior therapy with ruxolitinib

Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma)

Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator

Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK principal Investigator

Women of reproductive potential† must have a negative Serum ß human chorionic gonadotropin (ß-HCG) pregnancy test.

A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in East White Plains?

Yes, this clinical trial (NCT02974647) has an active research site in East White Plains, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

T Cell Lymphoma Treatment Options in East White Plains, NY

If you're searching for t cell lymphoma treatment options in East White Plains, NY, this clinical trial (NCT02974647) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our East White Plains research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced t cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all t cell lymphoma clinical trials near you to find additional studies recruiting in your area.

T Cell Lymphoma Clinical Trial in East White Plains, NY

Expert Care in East White Plains

IRB Approved

No-Cost Care

Apply for This East White Plains Location

Why Participate?

Simple Process